This news article has expired. Below you will find a short description about the news article and comments that were left by CancerCompass users.
Pfizer announced today results from studies evaluating the company's investigational anti- insulin growth factor- type 1 receptor (IGF-1R) antibody, figitumumab (CP-751,871), in patients with non-small cell lung cancer (NSCLC). A total of three abstracts were presented at the 45th Annual American Society of Clinical Oncology (ASCO) annual meeting in Orlando.
We care about your feedback. Let us know how we can improve your CancerCompass experience.